A name grouping together the four cerebral degenerative diseases of olivopontocerebellar atrophy, shy-drager syndrome, striatonigral degeneration, and one form of parkinson disease, considering them different forms of the same disease process.
(12 Dec 1998)
| Multiple system Atrophy Classification and external resources |
|
| ICD-10 |
G90.3 |
|---|---|
| ICD-9 | 333.0 |
| DiseasesDB | 8441 |
| eMedicine | neuro/671 |
| MeSH | D019578 |
Multiple system atrophy (MSA) is a degenerative neurological disorder.
MSA is characterized by a combination of the following:
When autonomic failure predominates, the term Shy-Drager syndrome
MSA is associated with the degeneration of nerve cells in specific areas of the brain. This cell degeneration causes problems with movement, balance and automatic functions of the body such as bladder control.
The cause of MSA is unknown and no specific risk factors have been identified.[1]
For men, the first sign is often erectile dysfunction (unable to achieve or sustain an erection). Both men and women often experience problems with their bladders including urgency, frequency, incomplete bladder emptying or an inability to pass urine (retention).
As the disease progresses three groups of symptoms predominate. These are:
Not all patients experience all of these symptoms.
MSA usually progresses more quickly than Parkinson's disease.[2]There is no remission from the disease. The remaining lifespan after the onset of symptoms is on average about 9 years.[3] Almost 80% of patients are disabled within 5 years of onset of the motor symptoms, and only 20% survive past 12 years.[citation needed] Rate of progression differs in every case and speed of decline may vary widely in individual patients.
There is no cure for MSA, so treatment involves treating the symptoms.
Management by rehabilitation professionals (physiotherapists, occupational therapists, speech therapists, and others) for problems with walking/movement, daily tasks, and speech problems is essential. Also social workers can help with coping with disability and access to health care services, both for the person with MSA as well as his/her family caregivers.
One particularly serious problem, the drop in blood pressure upon standing up (with risk of fainting thus injury from falling) often responds to fludrocortisone, a synthetic mineralocorticoid. Another common drug treatment is midodrine (an alpha-agonist.) Non-drug treatments include "head-up tilt" (elevating the head of the whole bed by about 10 degrees), salt tablets, generous intake of fluids, and pressure (elastic) stockings. Avoidance of triggers of low blood pressure (e.g. hot weather, alcohol, dehydration) are crucial.
Levdopa (L-Dopa) often only transiently or does not alleviate the parkinsonian symptoms of most MSA patients. In fact, poor response to L-Dopa has been suggested as a possible element in the differential diagnosis of MSA from Parkinson's disease.
Ongoing care from a neurologist specialized in "movement disorders" is recommended as the complex symptoms of MSA are often not familiar to less-specialized health care professionals.
Hospice/homecare services can be very useful as disability progresses.
In some cases, a diagnosis of MSA can only be confirmed post-mortem. When brain tissue of a person with MSA is examined under a microscope, structures called glial cytoplasmic inclusion bodies are visible. The presence of these inclusions (also known as Papp-Lantos bodies) in the movement, balance and automatic control centres of the brain are the defining histopathologic hallmark of MSA.
Other terms have been used to refer to this disorder, based on the predominant systems presented. These terms and their distinctions have been dropped in recent (1996 onwards) medical usage[4] and replaced with MSA subtype naming, but are helpful to understanding the older literature about this disease:
| Name | Characteristics | Abbreviation |
| Striatonigral degeneration |
predominating Parkinson's-like symptoms | MSA-p, "p" = parkinsonian subtype |
| Shy-Drager syndrome | characterized by Parkinsonism plus a more pronounced failure of the autonomic nervous system[5] | MSA-a, "a" = autonomic dysfunction subtype |
| Sporadic Olivopontocerebellar atrophy |
characterized by progressive ataxia (an inability to coordinate voluntary muscular movements) of the gait and arms and dysarthria (difficulty in articulating words) | MSA - c, "c" = cerebellar dysfunction subtype |
This article is based on an article from Wikipedia, the free encyclopedia and is available
under the terms of
GNU Free Documentation License.
In the Wikipedia there is a
list with all authors of this article
available.
Comments for Multiple system atrophy:
No Comments found for Multiple system atrophy